Zenabis Global — Investor Presentation (January 2021)
31 slides from Zenabis Global's investor presentation, Jan 4, 2021
Slide 1: Corporate Presentation
Corporate Presentation January 4, 2021 TSX: ZENA
Slide 2: Disclaimers
Disclaimers IMPORTANT: YOU MUST READ THE FOLLOWING BEFORE CONTINUING. The information contained in this document has been prepared by Zenabis Global Inc. (“Zenabis” or the “Company”). The information contained in this document (a) is provided as at the date hereof and is accurate only as of the date
Slide 3: Corporate Highlights
CORPORATE HIGHLIGHTS Three Sequential Quarters of Positive Adjusted EBITDA Low Cash Costs of Cultivation Given Scale ($0.76/g)1 111,200 kg of Licensed Cultivation Capacity Across Three Facilities Highly Recognizable Brands Ongoing Shipments to Nine Provinces, Three Territories, and Three Internation
Slide 4: Company Snapshot
COMPANY SNAPSHOT Zenabis Global Inc. is a significant Canadian cultivator of medical and adult-use recreational cannabis. As of December 2020, Zenabis divested its propagation TSX: ZENA business to become a pure-play cannabis cultivator. 2019-2020 2021+ Cannabis Operations In December 2020, ▪ Signif
Slide 5: 2020 Progress
2020 PROGRESS Zenabis made substantial operational and financial progress in 2020, positioning the company well for 2021 Debt Reduction ▪ 2020 Actions: Zenabis reduced total debt by approximately $76m, or 54% (see slide 19) ▪ 2021 Impact: Zenabis’ cash interest payments have decreased significantly,
Slide 6: Bevo Divestiture Overview
BEVO DIVESTITURE OVERVIEW Transaction Overview ▪ Commitment to Core Business. The disposition of the propagation business will enable Zenabis to focus on its core business of producing and selling cannabis and value-add cannabis products ▪ Continuity of Zenabis Langley. Zenabis can continue to opera
Slide 7: Our Facilities
OUR FACILITIES Zenabis' unique mix of facilities combines indoor and closed-greenhouse cultivation at scale with dedicated processing, fulfilment, and value-add manufacturing centres 2. Zenabis Langley1 Langley, British Columbia 1. Zenabis Atholville 3. Zenabis Stellarton Atholville, New Brunswick S
Slide 8: Production Footprint
PRODUCTION FOOTPRINT Zenabis Atholville Zenabis Langley Zenabis Stellarton Atholville, NB Langley, BC Stellarton, NS Parcel Size 871,000 sq. ft. N/A 547,000 sq. ft. Total Facility Space 380,000 sq. ft. 435,600 sq. ft. (leased) 255,000 sq. ft. Current Licensed Capacity 46,300 kg 64,100 kg 800 kg Expe
Slide 9: Recreational Brands
RECREATIONAL BRANDS Nature’s Inspiration Remember to Re-Üp Namaste exists to make it easy for people to return to their Re-up exists to democratize laughter. A brand that doesn’t true nature. Natural, approachable, simple and intelligently take itself too seriously and embraces the fun, lighthearted
Slide 10: Cannabis 2.0 Portfolio
CANNABIS 2.0 PORTFOLIO 2.0 Products PAX Vaporizing Cartridges ▪ Zenabis has five types of PAX Era Pods ▪ Zenabis is one of five Licensed Producers to launch PAX Era Pods (vaporizing cartridges) for PAX Labs Inc.’s high- tech oil vaporizers ̶ PAX Era Pods are dependable, leak-resistant and clog-free,
Slide 11: Product Portfolio
PRODUCT PORTFOLIO Current Products Dried Flower Pre-Rolls PAX Vaporizing Cartridges 510 Vaporizing Cartridges Oils Tinctures and Sprays Softgel Capsules Future Products Under Consideration for Near-Term Launch Edibles Gummies Hash 10
Slide 12: Domestic Partnerships and Distribution Channels
DOMESTIC PARTNERSHIPS AND DISTRIBUTION CHANNELS Zenabis has developed a diverse set of partnerships and relationships with provinces1, distributors, pharmacies and First Nations. Supply agreement Supply agreement primarily for oil for medical cannabis products Yukon Liquor Corporation (“YLC”) Northw
Slide 13: Growing International Distribution
GROWING INTERNATIONAL DISTRIBUTION Germany Malta Israel Australia Zenabis, through ZenPharm (see Zenabis has received conditional Zenabis ships cannabis to two Zenabis ships packaged, medical Malta) has entered into a binding approval to develop a production and counterparties in Israel, with cannab
Slide 14: ZenPharm
ZENPHARM Zenabis has obtained EU GMP approval from its Malta-based European partner, ZenPharm Limited. Through this joint venture, Zenabis can now supply the European medical market. Zenabis completed its first commercial sale to ZenPharm in December 2020. Europe Zenabis’ EU GMP approval enables the
Slide 15: Recent Developments
RECENT DEVELOPMENTS Zenabis has significantly increased shipments domestically and internationally, diversified its product offerings, and delivered positive Adjusted EBITDA throughout 2020. Corporate Updates EU GMP Approval and Term • Granted GACP quality certification by the CUMCS, which is a requ
Slide 16: Management
MANAGEMENT Shai Altman Eric Rasmussen Chief Executive Officer Chief Financial Officer ▪ Over 20 years of leadership in the consumer packaged ▪ Extensive senior management experience in publicly-listed goods industry, with 11 years of focused experience in the companies, both in North America and Eur
Slide 17: Board of Directors
BOARD OF DIRECTORS Daniel Burns Monty Sikka Shai Altman Chair Co-Founder and Director Chief Executive Officer and Director ▪ A lawyer, accountant and ▪ Co-founder of Zenabis ▪ Over 20 years of leadership in the entrepreneur ▪ As President of the Monark Group, consumer packaged goods ▪ Experienced co
Slide 18: Financial Progress
FINANCIAL PROGRESS Zenabis has made significant financial progress over the past seven quarters. The operational rationalization in early 2020 has resulted in three consecutive quarters of positive adjusted EBITDA and notable improvements in operating cash flow. Financial Progress – Past Seven Quart
Slide 19: Selected Financial Information
SELECTED FINANCIAL INFORMATION Selected Financial Metrics Cash as of December 31 2020 $4.8m Debt as of December 31 2020 $65.1m1 Market Capitalization $42.0m2 Enterprise Value $102.3m2 Financial Results Q3 2020 Gross Revenue3 $28.5m Net Revenue3 $23.7m Net Loss3,4 ($17.0m) Adjusted EBITDA5 $3.5m Bala
Slide 20: Recent Capital Structure Changes
RECENT CAPITAL STRUCTURE CHANGES Zenabis has implemented many deleveraging initiatives since June 2020, which have resulted in total debt reductions of $58.7m. Principal Principal Principal Debt Changes due Principal Principal Outstanding at Debt Outstanding at Payments / to Bevo Outstanding at Inte
Slide 21: Ongoing Cash Interest Payments
ONGOING CASH INTEREST PAYMENTS The below table outlines Zenabis’ ongoing cash interest payments as of January 4, 2021. Principal Outstanding at Debt Interest Rate Quarterly Interest Payment January 4, 2021 Secured Debentures $51.4m 14.0% $1.80m RDC Mortgage $2.0m 6.0% $0.03m Unsecured Convertible De
Slide 22: Comparable Production and Revenue Multiples
COMPARABLE PRODUCTION AND REVENUE MULTIPLES1 Current Licensed Annual Production Capacity Metrics CRON VFF ACB SNDL APHA OGI TGOD VIVO FIRE AH ZENA Enterprise Value2 ($m) 1,734 819 2,320 652 2,561 483 151 45 133 162 102 Current Capacity (kg) 40,150 37,500 150,000 60,000 255,000 89,000 32,000 14,500 5
Slide 23: Contact Us
TSX: ZENA Contact Us invest@zenabis.com www.zenabis.com
Slide 24: Appendix A – Facilities
ic 7 ae a> / Mer i =~. — Dy i a Ben Hi
Slide 25: Zenabis Atholville
ZENABIS ATHOLVILLE Zenabis Atholville is Zenabis’ largest indoor facility. This facility is expected to produce 46,300kg of dried cannabis equivalent per year operating at a steady state. Facility Details Description Location Atholville, New Brunswick Type and Size 380k sq. ft. indoor cannabis Statu
Slide 26: Zenabis Langley
ZENABIS LANGLEY Zenabis Langley is one of the largest greenhouses in Canada with advanced propagation technology. The facility is expected to produce 96,100kg1 of dried cannabis equivalent per year upon full buildout and operates at a steady state. Facility Details Description Location Langley, Brit
Slide 27: Zenabis Stellarton
ZENABIS STELLARTON Zenabis Stellarton is a licensed indoor facility located in Stellarton, Nova Scotia. The facility is intended to be utilized primarily as a processing, packaging and fulfillment centre as well as a manufacturing facility for value-add products. Facility Details Description Locatio
Slide 28: Appendix B – Financial Information
Appendix B – Financial Information
Slide 29: Debt Outstanding
DEBT OUTSTANDING Debt Summary Principal Amount Facility Description at January 4, 2021 ▪ Unsecured convertible debentures with interest rate of 6.0% Unsecured Convertible ▪ Convertible into Zenabis shares at $2.6087 per share $3.8m Debentures ▪ 825,000 warrants with exercise price of $2.68 ▪ Matures
Slide 30: Capitalization
CAPITALIZATION The following outlines the capitalization of Zenabis. Capitalization Enterprise Value Fully Diluted Shares Outstanding Value Enterprise Value Calculation Value Basic Shares Outstanding1 799,983,791 Basic Shares Outstanding 799,983,791 Plus: Deferred Stock Units 1,125,000 Times: Zenabi
Slide 31: Adjusted EBITDA Calculation
ADJUSTED EBITDA CALCULATION The following outlines the calculation to arrive at adjusted EBITDA. Adjusted EBITDA Calculation Q3 20201 Q2 20202 Q1 20203 Q4 20194 Net Loss (16,975,019) (15,781,932) (7,702,835) (98,714,311) Plus: Realized Fair Value Amounts Included in Inventory Sold 19,114,863 19,252,
Zenabis Global — Investor Presentation (January 2021) on 6ix